Dolutegravir, Lamivudine

Dovato 50 MG/300 MG Comprimidos Recubiertos con Pelicula

52.6 mg + 300 mg comprimido recubierto con películaSpainAuthorisedAuthorised 17 May 2022

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Dolutegravir, Lamivudine

Dovato 50 MG/300 MG Comprimidos Recubiertos con Pelicula

52.6 mg + 300 mg comprimido recubierto con películaSpainAuthorisedAuthorised 17 May 2022

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Romania · 50mg/300mg · compr. film. · Viiv Healthcare BV

Dovato®Serbia · 50mg+300mg · film tableta · Evropa Lek Pharma D.O.O. Beograd

DovatoSaudi Arabia · Glaxowellcome

DovatoSaudi Arabia · Glaxosmithkline (GSK)

Dovato Film-Coated Tablet 50MG/300MGSingapore · 50 mg + 300 mg · tablet, film coated · Glaxosmithkline Pte LTD

DovatoUnited States · 50MG BASE; 300MG · tablet · Viiv Hlthcare

Dolutegravir and LamivudineUnited States · 300MG · tablet · Emcure Pharms LTD

lamivudina + dolutegravir sódicoBrazil · Blanver Farmoquimica e Farmaceutica S.A.

lamivudina + dolutegravir sódicoBrazil · Fundação Oswaldo Cruz

Packs

Pack	Code	Status
DOVATO 50 MG/300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA, 30 comprimidos	743274

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substances: Dolutegravir, Lamivudine
Strength: 52.6 mg + 300 mg
Dosage form: comprimido recubierto con película
Route: vía oral
Register: Spain (AEMPS)
Status: Authorised
Status in the register: Autorizado, no comercializado
Authorised: 17 May 2022
Registration: 191370001IP
Marketing authorisation holder: Viiv Healthcare B.V.
Procedure: EU centralised
Supply: Uso Hospitalario